These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
130 related items for PubMed ID: 9917008
1. Enzymatic deacylation of teicoplanin followed by reductive alkylation: synthesis and antibacterial activity of new glycopeptides. Snyder NJ, Cooper RD, Briggs BS, Zmijewski M, Mullen DL, Kaiser RE, Nicas TI. J Antibiot (Tokyo); 1998 Oct; 51(10):945-51. PubMed ID: 9917008 [Abstract] [Full Text] [Related]
2. New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci. Malabarba A, Ciabatti R, Scotti R, Goldstein BP, Ferrari P, Kurz M, Andreini BP, Denaro M. J Antibiot (Tokyo); 1995 Aug; 48(8):869-83. PubMed ID: 7592033 [Abstract] [Full Text] [Related]
3. Synthesis and antibacterial activity of derivatives of the glycopeptide antibiotic A-40926 N-alkylated at the aminoglucuronyl moiety. Pavlov AY, Preobrazhenskaya MN, Malabarba A, Ciabatti R. J Antibiot (Tokyo); 1998 May; 51(5):525-7. PubMed ID: 9666185 [No Abstract] [Full Text] [Related]
4. Synthesis and antibacterial activity of alkyl derivatives of the glycopeptide antibiotic A40926 and their amides. Maffioli SI, Ciabatti R, Romanò G, Marzorati E, Preobrazhenskaya M, Pavlov A. Bioorg Med Chem Lett; 2005 Aug 15; 15(16):3801-5. PubMed ID: 15993054 [Abstract] [Full Text] [Related]
6. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin. Harland S, Tebbs SE, Elliott TS. J Antimicrob Chemother; 1998 Feb 15; 41(2):273-6. PubMed ID: 9533471 [Abstract] [Full Text] [Related]
7. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns. Marchese A, Debbia EA, Bacca D, Balistreri G, Musolino B, Schito GC. Drugs; 1997 Feb 15; 54 Suppl 6():11-20. PubMed ID: 9474477 [Abstract] [Full Text] [Related]
10. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. Bartoloni A, Colao MG, Orsi A, Dei R, Giganti E, Parenti F. J Antimicrob Chemother; 1990 Nov 15; 26(5):627-33. PubMed ID: 1688341 [Abstract] [Full Text] [Related]
11. Synthesis of hydrophobic N'-mono and N',N"-double alkylated eremomycins inhibiting the transglycosylation stage of bacterial cell wall biosynthesis. Pavlov AY, Miroshnikova OV, Printsevskaya SS, Olsufyeva EN, Preobrazhenskaya MN, Goldman RC, Branstrom AA, Baizman ER, Longley CB. J Antibiot (Tokyo); 2001 May 15; 54(5):455-9. PubMed ID: 11480890 [Abstract] [Full Text] [Related]
14. Lipophilic teicoplanin pseudoaglycon derivatives are active against vancomycin- and teicoplanin-resistant enterococci. Szűcs Z, Bereczki I, Csávás M, Rőth E, Borbás A, Batta G, Ostorházi E, Szatmári R, Herczegh P. J Antibiot (Tokyo); 2017 May 15; 70(5):664-670. PubMed ID: 28144040 [Abstract] [Full Text] [Related]
16. In vitro activity of teicoplanin against gram-positive cocci. Allouch P, Pina P, Chaplain C, Delarbre JM, Geffroy F, Grasmick CP, Marcolin M, Morel A, Pangon B, Rio Y, Sédaillan A. Pathol Biol (Paris); 2000 Oct 15; 48(8):792-5. PubMed ID: 11244609 [Abstract] [Full Text] [Related]